Merck known as MSD outside the United States and Canada, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the conditional approval of WELIREG® (belzutifan), an oral hypoxia-inducible factor-2…
SonarMD, a leading platform for value-based care (VBC) focused on complex, chronic gastrointestinal conditions, has presented new clinical findings at the Advances in Inflammatory Bowel Diseases (AIBD) conference in Orlando, FL (December 9-11, 2024). The findings highlight the significant link…
City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S., presented groundbreaking findings at the ASH Annual Conference in San Diego from Dec. 7 to 10. Recognized among the nation’s top five…
Bio-Techne Corporation announced the launch of a highly sensitive ESR1 mutation monitoring assay through its Asuragen brand. This innovative assay is designed for research use and aims to detect ESR1 gene mutations associated with hormone receptor-positive (HR+) metastatic breast cancer.…
Genmab has announced promising results from the Phase 1b/2 EPCORE® NHL-2 trial, which evaluated a fixed-duration regimen of epcoritamab, a T-cell engaging bispecific antibody, in combination with lenalidomide and rituximab (R2) in adult patients with relapsed or refractory (R/R) follicular…
Incyte has announced promising results from the Phase 3 POD1UM-304 trial evaluating retifanlimab (Zynyz®), a PD-1-targeting monoclonal antibody, in combination with platinum-based chemotherapy for adults with previously untreated metastatic non-small cell lung cancer (NSCLC). The trial included patients with both…
AbbVie has unveiled key findings from its latest Emotional Impact Report (EIR), offering insights into the mental health challenges faced by patients with chronic lymphocytic leukemia (CLL). For the first time, the survey highlights the unique emotional experiences of Hispanic,…
Stoke Therapeutics has announced new data from its Phase 1/2a and open-label extension (OLE) studies on zorevunersen, a potential disease-modifying treatment for Dravet syndrome. The data revealed significant and lasting reductions in convulsive seizure frequency in patients who received zorevunersen…
Eisai and Biogen Inc. have announced that Mexico’s Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has approved LEQEMBI (lecanemab), a humanized monoclonal antibody, for the treatment of early Alzheimer’s disease (AD). This approval marks an important step in…
CVS Health Corporation has disclosed the Reference Yield and Total Consideration for its previously announced cash tender offer (the “Any and All Tender Offer”) targeting its 4.100% Senior Notes due 2025 (the “Any and All Notes”). This tender offer is…
GSK plc and Medicines for Malaria Venture (MMV) have announced a major milestone in the fight against malaria, as the World Health Organization (WHO) has awarded prequalification to tafenoquine. This is the first single-dose medicine for the prevention of relapse…
Teva Pharmaceutical Industries has announced encouraging results from its Phase 3 SPACE study, which evaluated the efficacy and safety of AJOVY (fremanezumab) for preventing episodic migraines in children and adolescents aged 6 to 17 years. The study demonstrated a statistically…